Objective: To investigate the safety and efficacy of mitoxantrone liposome in the treatment of children with high-risk acute myeloid leukemia (AML).
Methods: The children with high-risk AML who received the mitoxantrone liposome regimen at Wuhan Children's Hospital from January 2022 to February 2023 were collected as the observation group, and the children with high-risk AML who received idarubicin regimen were enrolled as controls, and their clinical data were analyzed. Time to bone marrow recovery, the complete remission rate of bone marrow cytology, the clearance rate of minimal residual disease, and treatment-related adverse reactions were compared between the two groups.
Results: The patients treated with mitoxantrone liposome showed shorter time to recovery of leukocytes(17 21 day), granulocytes(18 24 day), platelets(17 24 day), and hemoglobin(20 26 day) compared with those treated with idarubicin, there were statistical differences ( <0.05). The effective rate and MRD turning negative rate in the observation group were 90.9% and 72.7%, respectively, while those in the control group were 94.1% and 76.4%, with no statistical difference ( >0.05). The overall response rate of the two groups of patients was similar.
Conclusion: The efficacy of mitoxantrone liposome is not inferior to that of idarubicin in children with high-risk AML, but mitoxantrone liposome allows a significantly shorter duration of bone marrow suppression and the safety is better.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.19746/j.cnki.issn.1009-2137.2024.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Liposomal mitoxantrone monotherapy in patients with relapsed or refractory mature T-cell and natural killer-cell neoplasms: A phase 2, multicenter, open-label, single-arm trial.
Cancer
January 2025
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center, Guangzhou, China.
Introduction: The prognosis of relapsed or refractory mature T- and natural killer (NK)-cell lymphoma remains dismal. Novel agents are urgently needed to improve the outcomes for this population.
Methods: In this phase 2, multicenter, open-label, single-arm study (NCT03776279), the authors report the efficacy and safety of liposomal mitoxantrone (Lipo-MIT) monotherapy in patients with relapsed or refractory mature T- and NK-cell lymphoma.
Targeted Delivery Strategy of Indocyanine Green-Mitoxantrone Loaded Liposomes Co-Modified with BTP-7 and BR2 For the Treatment of Glioma.
Pharm Dev Technol
January 2025
Guangxi Key Laboratory of Special Biomedicine; School of Medicine, Guangxi University, Nanning, 530004, China.
Article Synopsis
- The study focuses on creating a new drug delivery system using dual-ligand-modified liposomes to target glioma, with the goal of overcoming the blood-brain barrier and improving drug effectiveness.
- Researchers used a specific technique to prepare liposomes that co-load a photosensitizer (ICG) and a chemotherapeutic drug (MTO), and tested their properties and ability to penetrate the blood-brain barrier while targeting glioma cells.
- Results showed that the modified liposomes were stable, capable of effectively penetrating the blood-brain barrier, concentrating in glioma cells, and exhibited strong anti-tumor effects, highlighting their potential in improving glioma treatment.
Efficacy of the CV‑MED regimen in treating extramedullary involvement of multiple myeloma: A case report.
Oncol Lett
December 2024
Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, Beijing 100191, P.R. China.
Extramedullary progression of multiple myeloma (MM) is commonly associated with a poor prognosis. However, optimal management strategies have not yet been established for the treatment of extramedullary involvement in MM. The present study reports the case of a 59-year-old female patient with MM who experienced extramedullary progression after two cycles of first-line VRD (bortezomib, lenalidomide and dexamethasone) therapy.
View Article and Find Full Text PDFTargeted Liposomal Co-delivery of an Immunogenic Cell Death Inducer and a Toll-Like Receptor 4 Agonist for Enhanced Cancer Chemo-immunotherapy.
ACS Appl Mater Interfaces
August 2024
Department of Chemical and Biomolecular Engineering, Korea Advanced Institute of Science and Technology (KAIST), Daejeon 34141, Republic of Korea.
Anticancer chemo-immunotherapy has gained considerable attention across various scientific domains as a prospective approach for the comprehensive eradication of malignant tumors. Recent research has particularly been focused on traditional anthracycline chemo drugs, such as doxorubicin and mitoxantrone. These compounds trigger apoptosis in tumor cells and evoke immunogenic cell death (ICD).
View Article and Find Full Text PDFTailoring Phage Nanosomes for Enhanced Theranostic Properties of Near Infrared Dyes.
Langmuir
August 2024
Department of Biomedical Engineering, IIT Hyderabad, Kandi, Telangana 502284, India.
Near-infrared (NIR) phototherapies offer noninvasive, cost-effective solutions for treating tumors and microbial infections. However, organic NIR dyes commonly used suffer from solubility and stability issues requiring frequent dosing. We address this challenge by exploring the bacteriophage-mediated enhancement of NIR dye properties.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!